HEALEY ALS Platform Trial - Regimen C CNM-Au8

• Status: Enrolling by invitation
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Regimen C will evaluate the safety and efficacy of a single study drug, CNM-Au8, in participants with ALS.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merit E. Cudkowicz, MD
• Collaborator: Clene Nanomedicine

Criteria

Inclusion Criteria:

• No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).

Exclusion Criteria:

• The following exclusion criterion is in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).

1. History of allergy to gold, gold salts, or colloidal gold preparations.